Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report.
증례보고
1/5 보강
Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunoth
APA
Bertolina C, Bertolotti M, et al. (2026). Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report.. Dermatology reports, 18(1). https://doi.org/10.4081/dr.2025.10324
MLA
Bertolina C, et al.. "Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report.." Dermatology reports, vol. 18, no. 1, 2026.
PMID
40525794 ↗
Abstract 한글 요약
Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- The Role of Vitamins and Micronutrients in the Prevention of Melanoma: A Review of Current Evidence.
- Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report.
- Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer : (Ki67 and inflammation in triple-negative breast cancer).
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis.